


# Tanox, Inc.



4888 Loop Central Dr.  
Suite 820  
Houston, TX 77081  
(713) 578-4000  
Fax: (713) 578-5002

## FAX TRANSMISSION COVER SHEET

**Date:** March 6, 2003  
**To:** Office of Initial Patent Examination  
**Company:** United States Patent & Trademark Office  
**Fax:** 703 308-7751  
**Sender:** Cheryl A. Liljestrand  
**RE:** Response to Notice to File Missing Parts

You should receive <sup>3</sup> page(s), including this cover.  
If you do not receive all pages, please call (713) 578-4182.

Application No: 10/071,962  
Filed: February 8, 2002  
For: G-CSF RECEPTOR AGONIST ANTIBODIES AND SCREENING METHODS THEREFOR

1. Response to Notice to Comply
2. Copy of Notice
3. Copy of Original Complying Response filed July 10, 2002
4. Copy of Certificate of Transmission


### Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703)308-7751, on March 6, 2003.

Typed or printed name of person signing this certificate:  
Cheryl A. Liljestrand

Signature: Cheryl Liljestrand

# Tanox, Inc.



4888 Loop Central Dr.  
Suite 820  
Houston, TX 77081  
(713) 578-4000  
Fax: (713) 578-5002

## FAX TRANSMISSION COVER SHEET

**Date:** July 10, 2002  
**To:** Office of Initial Patent Examination  
**Company:** United States Patent & Trademark Office  
**Fax:** 703 308-7751  
**Sender:** Cheryl A. Liljestrand  
**RE:** Response to Notice to File Missing Parts

You should receive 8 page(s), including this cover.  
If you do not receive all pages, please call (713) 578-4182.

Application No: 10/071,962  
Filed: February 8, 2002  
For: G-CSF RECEPTOR AGONIST ANTIBODIES AND SCREENING METHODS  
THEREFOR

1. Response to Notice to File Missing Parts with Notice
2. Copy of Declaration
3. Notice to File Missing parts
4. Petition for one month extension of time

### Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703)308-7751, on July 10, 2002.

Typed or printed name of person signing this certificate:

Cheryl A. Liljestrand

Signature: Cheryl A. Liljestrand

PATENT  
ATTORNEY DOCKET NO.: TNX98-03-01  
CUSTOMER NO: 26839

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:  
Ni, Paul et al.

Serial No.: 10/071,962

Filed: February 8, 2002

For: G-CSF RECEPTOR AGONIST  
ANTIBODIES AND SCREENING  
METHODS THEREFOR

Group Art Unit: 1647

Examiner: L. Spector

Assistant Commissioner for Patents  
Washington, D.C. 20231


Dear Sir:

**RESPONSE TO THE NOTICE TO FILE MISSING PARTS**

In response to the Notice of Missing Parts dated April 10, 2002, Applicants hereby submit a copy of the declaration filed in the parent Application No. 09/303,155. Please charge the surcharge of \$65.00 to our deposit account 20-0087.

In compliance with the Sequence Listing requirements of 37 C.F.R. §1.821 (b) through (f), Applicants submitted a Sequence Listing with the application when filed on February 8, 2002. The paper copy of the Sequence Listing in this application is identical to the computer readable copy of the Sequence Listing filed in the parent application, Serial No. 09/303,155 on April 30, 1999. In accordance with 37 CFR 1.821(e), please use the computer readable form (CRF) filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. In compliance with the rules under 37 CFR 1.821(f), I hereby state that the information written sequence listing filed with the current application on February 8, 2002 is identical to that contained in the CRF.

Dated: July 10, 2002.

Respectfully Submitted  
BY:   
Cheryl A. Liljestrand  
Reg. No. 45,275



## UNITED STATES PATENT AND TRADEMARK OFFICE


COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/071,962	02/08/2002	Baofu Ni	TNX 98-03-01

26839  
TANOX, INC.  
10301 STELLA LINK  
HOUSTON, TX 77025

CONFIRMATION NO. 2802

## FORMALITIES LETTER



\*0000000008721129\*

Date Mailed: 09/04/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*